Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.81
Nov 16 • 3:59 PM ET Dollar change-0.28 Percentage change(-6.85%)
Aftermarket Close
3.81
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Nov 12, 6:45 PMAzora Therapeutics reports fiscal Q3 2026 non-GAAP EPS of $-4.52 (-133% YoY), missing estimates, and revenue of $0, beating estimates
Index
-
Market Cap
54.43M
Enterprise Value
94.73M
Income
-120.57M
Sales
0.00M
Book/sh
-14.61
Cash/sh
1.54
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
6
IPO
Jul 27, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
2.47
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
5.63
Current Ratio
5.63
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-19.04
EPS next Y
-0.59
EPS next Q
-0.16
EPS this Y
45.79%
EPS next Y
90.88%
EPS next 5Y
57.59%
EPS past 3/5Y
88.55% 53.46%
Sales past 3/5Y
- -
EPS Y/Y TTM
17.76%
Sales Y/Y TTM
-
EPS Q/Q
-123.29%
Sales Q/Q
-
Insider Own
-
Insider Trans
-
Inst Own
5.65%
Inst Trans
-
ROA
-855.47%
ROE
-265.94%
ROIC
-503.04%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-4.34%
SMA50
-9.47%
SMA200
21.73%
Trades
Shs Outstand
14.29M
Shs Float
2.38M
52W High
8.25 -53.82%
52W Low
1.31 190.84%
Volatility
13.55% 17.05%
ATR (14)
0.57
RSI (14)
47.82
Beta
1.62
Rel Volume
0.16
Avg Volume
51.33K
Volume
8,042
Perf Week
1.60%
Perf Month
9.17%
Perf Quarter
-30.09%
Perf Half Y
136.65%
Perf YTD
-30.73%
Perf Year
-53.12%
Perf 3Y
-92.53%
Perf 5Y
-99.81%
Perf 10Y
-
Prev Close
4.09
Price
3.81
Change %
-6.85%
Consensus
Strong Buy
Avg. Price Target
$10.67
Implied Upside
+180.1%
Analysts5incl. previous ratings
Rating Distribution5 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 02, 2026Initiated
TD logoTTD Cowen
Buy
Aug 03, 2026Initiated
AAlliance Global Partners
Buy$11+188.7%
Nov 14, 2024Initiated
RRodman & Renshaw
Buy$8+110.0%
Oct 30, 2018Initiated
MMaxim Group
Buy$5+31.2%
Oct 11, 2018Initiated
DDawson James
Buy
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coastlands Capital LP10% OwnerJul 14 '26Buy2.652,0005,300387,075Jul 16 05:08 PM
Coastlands Capital LP10% OwnerJul 16 '26Buy2.751,2333,391388,308Jul 16 05:08 PM
Coastlands Capital LP10% OwnerJul 09 '26Buy2.7910,05328,048383,375Jul 13 10:30 AM
Coastlands Capital LP10% OwnerJul 10 '26Buy2.701,7004,590385,075Jul 13 10:30 AM
Coastlands Capital LP10% OwnerJun 29 '26Buy2.6025,00065,000373,322Jul 01 10:30 AM
Azora Therapeutics, Inc. is a biopharmaceutical company that develops therapies for immune-mediated inflammatory diseases. Its investigational oral drug, AT177, is being develop for inflammatory bowel diseases, with an initial focus on ulcerative colitis. The company was founded by Julie Saiki and Matthew Davidson which is headquartered in Los Angeles, CA.
PhDMatthew Davidson